Adrenergic Receptor Activators

Cat.No.	Product Name	Information	Product Use Citations	Product Validations
S3764	Isoferulic Acid	Isoferulic acid (Hesperetic acid, Hesperetate, Isoferulate), a major active ingredient of Cimicifuga heracleifolia, shows anti-inflammatory, antiviral, antioxidant, and antidiabetic properties. Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC50=1.4 µM) to enhance secretion of β-endorphin (EC50=52.2 nM) and increase glucose use.
E0785	YS-49	YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells, inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1, also is an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors.	Cell Signal, 2025, 131:111752 Signal Transduct Target Ther, 2024, 9(1):243

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S3764

Isoferulic Acid

Isoferulic acid (Hesperetic acid, Hesperetate, Isoferulate), a major active ingredient of Cimicifuga heracleifolia, shows anti-inflammatory, antiviral, antioxidant, and antidiabetic properties. Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is a cinnamic acid derivative that has antidiabetic activity. Isoferulic acid binds to and activates α1-adrenergic receptors (IC50=1.4 µM) to enhance secretion of β-endorphin (EC50=52.2 nM) and increase glucose use.

E0785

YS-49

YS-49 is a PI3K/Akt (a downstream target of RhoA) activator, to reduce RhoA/PTEN activation in the 3-methylcholanthrene-treated cells, inhibits angiotensin II (Ang II)-stimulated proliferation of VSMCs via induction of heme oxygenase (HO)-1, also is an isoquinoline compound alkaloid, has a strong positive inotropic action through activation of cardiac β-adrenoceptors.

Cell Signal, 2025, 131:111752

Signal Transduct Target Ther, 2024, 9(1):243